Mr. Speaker, in fact, as the hon. member should know, my department some months ago created a new marketed health products directorate at Health Canada to increase surveillance, and especially post-market surveillance, in relation to adverse reactions and medication incidents. In fact, one of the reasons we did this was to ensure that we can in the future, working with physicians and others, avoid the kind of tragedy that befell Vanessa Young and her family.
In the House of Commons on March 26th, 2003. See this statement in context.